Wujutong Pharmaceutical

Beijing Wujutong Pharmaceutical Technology is a clinical-stage biopharmaceutical company focused on developing innovative ophthalmic treatments through advanced drug delivery technologies. The company specializes in creating sustained-release formulations designed to improve patient compliance and therapeutic efficacy for chronic ocular diseases such as glaucoma and dry eye syndrome. Its proprietary platform enables the controlled release of active pharmaceutical ingredients within the eye, reducing the frequency of administration. Wujutong's lead candidate, WJT-01, is a long-acting latanoprost formulation currently in Phase 2 clinical trials. The company aims to address significant unmet medical needs in the global ophthalmology market by bridging the gap between innovative drug delivery and clinical application.